临床与病理杂志2017，Vol.37Issue(3)：557-563,7.DOI:10.3978/j.issn.2095-6959.2017.03.019
阿帕替尼治疗53例晚期原发性肝癌的疗效
Effect of apatinib on treatment of 53 cases of advanced primary liver cancer
摘要
Abstract
Objective: To evaluate the curative effect and safety of apatinib on treatment of advanced primary liver cancer. Methods: Fifty-three patients of advanced primary liver cancer with much routine treatment were enrolled in the group. All the patients were randomly divided into the orally took apatinib 250, 500, 850 mg until the disease progressed or the patients could not tolerate. Efficacy and drug toxicity was observed after 21 months followed-up. Results: Response was assessed in all the 53 patients. The objective response rate (ORR) was 18.86% and the disease control rate (DCR) was 56.6%. The main adverse reactions were hypertension, hand-foot syndrome, proteinuria, fatigue, mostly degree Ⅰor Ⅱ, most of the patients tolerated. Conclusion: Apatinib is an effective drug for the treatment of advanced primary liver cancer, with an advantage of nice durability.关键词
阿帕替尼/原发肝癌/安全/有效Key words
apatinib/primary liver cancer/safety/effective引用本文复制引用
宋锦添,陈奕贵,许春伟,蔡雄超,陈丽珠..阿帕替尼治疗53例晚期原发性肝癌的疗效[J].临床与病理杂志,2017,37(3):557-563,7.基金项目
国家临床重点专科建设项目(2013).This work was supported by National Clinical Key Specialty Construction Program, P. R. China (2013). （2013）
